Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
63 hedge funds and large institutions have $11.9M invested in Endocyte, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 16 closing their positions.
16% less funds holding
Funds holding: 75 → 63 (-12)
35% less capital invested
Capital invested by funds: $18.4M → $11.9M (-$6.52M)
64% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 28
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
80% less call options, than puts
Call options by funds: $108K | Put options by funds: $542K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$271K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$243K |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$135K |
| 4 |
Renaissance Technologies
New York
|
+$120K |
| 5 |
Two Sigma Investments
New York
|
+$95.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.53M |
| 2 |
PA
Pinnacle Associates
New York
|
-$1.04M |
| 3 |
Goldman Sachs
New York
|
-$585K |
| 4 |
Morgan Stanley
New York
|
-$515K |
| 5 |
Millennium Management
New York
|
-$333K |
ECYT Hedge Fund Activity: Q3 2017 in Review
63 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2017, worth a combined $11.9M — down 35% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ECYT and 5 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 10 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $271K. The largest seller was Fidelity Investments, cutting an estimated $1.53M.
- 63 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2017, down from 75 in Q2 2017.
- Funds reported $11.9M of Endocyte, Inc. Common Stock stock for Q3 2017, down 35% quarter-over-quarter.
- 5 funds opened new Endocyte, Inc. Common Stock positions in Q3 2017 and 16 closed out, a net change of -11 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2017 was D.E. Shaw & Co, an estimated $271K added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $1.53M sold.
Based on aggregated 13F filings for Q3 2017.